| Non-Hodgkin Lymphoma (NHL) |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| CAR-T |
0 |
0.85 |
| Stem Cell Research and Therapy |
0 |
0.42 |
| Lymphoma |
0 |
0.37 |
| B-Cell Lymphoma |
0 |
0.98 |
| Transplantation |
0 |
0.97 |
| Refractory |
0 |
0.25 |
| Leukemia |
0 |
0.23 |
| Palliative Care |
0 |
0.2 |
| Antineoplastic Drug |
0 |
0.19 |
| Cancer |
0 |
0.19 |
| Healthcare and Medical Technology |
0 |
0.13 |
| Multiple Myeloma |
0 |
0.13 |
| Patient Safety |
0 |
0.13 |
| Adverse Effects |
0 |
0.12 |
| Clinical Research |
0 |
0.12 |
| Cytokines |
0 |
0.12 |
| New York |
0 |
0.12 |
| Texas |
0 |
0.12 |
| Antigens |
0 |
0.06 |
| Chemotherapy |
0 |
0.06 |
| Frailty |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| Receptors |
0 |
0.06 |